Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirofiban - Merck & Co

Drug Profile

Tirofiban - Merck & Co

Alternative Names: Aggrastat; L 462; L 700462; MK 0383; MK 383; Tirofiban HCl; Tirofiban hydrochloride

Latest Information Update: 11 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer 4P Therapeutics; Aspen Pharmacare; Correvio Pharma; Eddingpharm; Medicure
  • Class Antiplatelets; Aromatic amino acids; Ischaemic heart disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Arterial thrombosis; Myocardial infarction; Unstable angina pectoris
  • No development reported Coronary artery restenosis

Most Recent Events

  • 05 Dec 2019 Medicure initiates litigation against Nexus Pharmaceuticals over ANDA submission in USA
  • 23 Aug 2019 Medicure announce intension to enter into an licensing agreement with Gland Pharma to commercialise a generic tirofiban hydrochloride injection in the US
  • 21 Aug 2019 Medicure settles it patent infringement against Gland Pharma over ANDA submission in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top